Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies

Int Urol Nephrol. 2014 Sep;46(9):1715-28. doi: 10.1007/s11255-014-0703-4. Epub 2014 Apr 1.


Purpose: Several epidemiologic studies were performed to clarify the protective effect of regular aspirin use on prostate cancer risk; however, the results remain controversial. Therefore, we conducted this meta-analysis to assess the association between regular aspirin use and risk of prostate cancer.

Methods: Electronic databases including PubMed, EMBASE and Cochrane Library were searched between January 1966 and April 2013 to identify eligible studies. Pooled relative ratios (RRs) and 95 % confidence intervals (CIs) were computed to assess the influence of aspirin use on prostate cancer risk. All statistical tests were two-sided.

Results: A total of 24 observational studies including 14 case-control studies and 10 cohort studies were eligible for this meta-analysis. Regular aspirin use was associated with reduction in overall and advanced prostate cancer risk (pooled RR 0.86, 95 % CI 0.81-0.92; pooled RR 0.83, 95 % CI 0.75-0.91, respectively). When we restricted our analyses to studies with long-time regular aspirin use (equal or more than 4 years), reverse association became stronger (pooled RR 0.82, 95 % CI 0.72-0.93; pooled RR 0.70, 95 % CI 0.55-0.90, respectively).

Conclusions: Our findings suggest that regular, especially long-time regular aspirin use may reduce the risk of overall and advanced prostate cancer. Considering the limitation of included studies, further well-designed large-scaled cohort studies and RCTs are required to draw more definitive conclusions.

Publication types

  • Meta-Analysis

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Aspirin / therapeutic use*
  • Epidemiologic Studies
  • Humans
  • Male
  • Prostatic Neoplasms / epidemiology*
  • Prostatic Neoplasms / prevention & control*
  • Risk Assessment


  • Anti-Inflammatory Agents, Non-Steroidal
  • Aspirin